§ 379h–2.
(a)
Performance report
(1)
In general
Not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning—
(A)
the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 101(b)
1
See References in Text note below.
of the Prescription Drug User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals, including the status of the independent assessment described in such letters; and
(B)
the progress of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research in achieving the goals, and future plans for meeting the goals, including, for each review division—
(i)
the number of original standard new drug applications and biologics license applications filed per fiscal year for each review division;
(ii)
the number of original priority new drug applications and biologics license applications filed per fiscal year for each review division;
(iii)
the number of standard efficacy supplements filed per fiscal year for each review division;
(iv)
the number of priority efficacy supplements filed per fiscal year for each review division;
(v)
the number of applications filed for review under accelerated approval per fiscal year for each review division;
(vi)
the number of applications filed for review as fast track products per fiscal year for each review division;
(vii)
the number of applications filed for orphan-designated products per fiscal year for each review division;
(viii)
the number of breakthrough designations for a fiscal year for each review division; and
(ix)
the number of investigational new drug applications submitted per fiscal year, including for each review division.
(3)
Real time reporting
(B)
Data
The Secretary shall post the following data in accordance with subparagraph (A):
(i)
The number and titles of draft and final guidance on topics related to the process for the review of human drug applications, and whether such guidances were issued as required by statute or pursuant to a commitment under the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022.
(ii)
The number and titles of public meetings held on topics related to the process for the review of human drug applications, and whether such meetings were required by statute or pursuant to a commitment under the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022.
(iii)
The number of new drug applications and biological licensing applications approved.
(iv)
The number of new drug applications and biological licensing applications filed.
(v)
For fiscal years 2023 and 2024, of the meeting requests from sponsors for which the Secretary has determined that a face-to-face meeting is appropriate, the number of face-to-face meetings requested by sponsors to be conducted in person (in such manner as the Secretary shall prescribe on the website of the Food and Drug Administration), and the number of such in-person meetings granted by the Secretary, with both such numbers disaggregated by the relevant agency center.
(4)
Rationale for PDUFA program changes
The Secretary shall include in the annual report under paragraph (1)—
(A)
data, analysis, and discussion of the changes in the number of individuals hired as agreed upon in the letters described in section 1001(b) of the Prescription Drug User Fee Amendments of 2022 and the number of remaining vacancies, the number of full-time equivalents funded by fees collected pursuant to
section 379h of this title, and the number of full-time equivalents funded by budget authority at the Food and Drug Administration by each division within the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Office of Regulatory Affairs, and the Office of the Commissioner;
(B)
data, analysis, and discussion of the changes in the fee revenue amounts and costs for the process for the review of human drug applications, including identifying—
(i)
drivers of such changes; and
(ii)
changes in the average total cost per full-time equivalent in the prescription drug review program;
(C)
for each of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Office of Regulatory Affairs, and the Office of the Commissioner, the number of employees for whom time reporting is required and the number of employees for whom time reporting is not required; and
(D)
data, analysis, and discussion of the changes in the average full-time equivalent hours required to complete review of each type of human drug application.
(5)
Analysis
For each fiscal year, the Secretary shall include in the report under paragraph (1) an analysis of the following:
(A)
The difference between the aggregate number of human drug applications filed and the aggregate number of approvals, accounting for—
(i)
such applications filed during one fiscal year for which a decision is not scheduled to be made until the following fiscal year;
(ii)
the aggregate number of applications for each fiscal year that did not meet the goals identified in the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022 for the applicable fiscal year.
(B)
Relevant data to determine whether the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research have met performance enhancement goals identified in the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022 for the applicable fiscal year.
(C)
The most common causes and trends of external or other circumstances affecting the ability of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, Office of Regulatory Affairs, and the Food and Drug Administration to meet the review time and performance enhancement goals identified in the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022.
(c)
Corrective action report
For each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit a corrective action report to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate. The report shall include the following information, as applicable:
(2)
Goals missed
For any of the goals identified in the letters described in section 101(b) 1 of the Prescription Drug User Fee Amendments of 2022 for the applicable fiscal year that the Secretary determines to not have been met, the corrective action report shall include—
(A)
a detailed justification for such determination and a description, as applicable, of the types of circumstances and trends under which human drug applications that missed the review goal time were approved during the first cycle review, or application review goals were missed; and
(B)
with respect to performance enhancement goals that were not achieved, a description of efforts the Food and Drug Administration has put in place for the fiscal year in which the report is submitted to improve the ability of such agency to meet each such goal for the such fiscal year.
(f)
Reauthorization
(1)
Consultation
In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for the process for the review of human drug applications for the first 5 fiscal years after fiscal year 2027, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with—
(A)
the Committee on Energy and Commerce of the House of Representatives;
(B)
the Committee on Health, Education, Labor, and Pensions of the Senate;
(C)
scientific and academic experts;
(D)
health care professionals;
(E)
representatives of patient and consumer advocacy groups; and
(F)
the regulated industry.
(2)
Prior public input
Prior to beginning negotiations with the regulated industry on the reauthorization of this subpart, the Secretary shall—
(A)
publish a notice in the Federal Register requesting public input on the reauthorization;
(B)
hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in subsection (a);
(C)
provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes to this subpart; and
(D)
publish the comments on the Food and Drug Administration’s Internet Web site.
(3)
Periodic consultation
(5)
Public review of recommendations
After negotiations with the regulated industry, the Secretary shall—
(A)
present the recommendations developed under paragraph (1) to the Congressional committees specified in such paragraph;
(B)
publish such recommendations in the Federal Register;
(C)
provide for a period of 30 days for the public to provide written comments on such recommendations;
(D)
hold a meeting at which the public may present its views on such recommendations; and
(E)
after consideration of such public views and comments, revise such recommendations as necessary.
(6)
Transmittal of recommendations
(7)
Minutes of negotiation meetings
([June 25, 1938, ch. 675, § 736B], as added [Pub. L. 110–85, title I, § 105], Sept. 27, 2007, [121 Stat. 840]; amended [Pub. L. 112–144, title I, § 104], July 9, 2012, [126 Stat. 1000]; [Pub. L. 115–52, title I, § 103], title IX, §§ 903(a), 904(a), Aug. 18, 2017, [131 Stat. 1012], 1077, 1082; [Pub. L. 117–180, div. F, title I, § 1004], Sept. 30, 2022, [136 Stat. 2146]; [Pub. L. 117–328, div. FF, title III, § 3626(a)], Dec. 29, 2022, [136 Stat. 5883].)